AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06137495 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sensitization to House dust mites
Description: The SPT is performed at the time of diagnosis and after six-months follow-up period. Serum specific IgE is measured by immunoblotting, chemiluminescence, and ImmunoCAP assays
Study NCT02750917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lornoxicam
Description: At the end of surgery patients in group LORNOXICAM received one pill of 8 mg lornoxicam every 12 hours in the surgery day and first postoperative day.
Study NCT02750917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoricoxib
Description: At the end of surgery patients in the ETORICOXIB group received one pill of 120 mg etoricoxib at the end of surgery and a second one after 24 hours. This group also received placebo pills at 12 h, between the active pills.
Study NCT01955421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib 100mg qd
Study NCT01955421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib 250mg qd
Study NCT02306317 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard procedure
Description: FiO2 manually controlled by nursing
Study NCT02306317 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental procedure
Description: FiO2 manually controlled by parents, after training.
Study NCT03501719 — intervention group
Intervention type: DRUG
Intervention: Number of drugs in the ART regimen
Description: Triple therapy vs. dual therapy vs. monotherapy
Study NCT02462135 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual interactive memory training
Description: Training sessions of the VIMT group are divided into initial training and booster training. Each training session is 45 minutes/day, 3 sessions/week, for 12 weeks for both initial training and booster training (36 sessions each). The training content of the four memory training include: (1) spatial encoding memory training task, (2) updating-spatial memory training task, (3) updating-visual memory training task, and (4) rehearsal-visuospatial memory training task.
Study NCT02462135 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Passive information activities
Description: The active control group (Passive information activities) only accepts the initial training phase, which training content of the two types to include: (1) listening to audio books, and (2) reading online newspaper.
Study NCT03688594 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: NIPT Test
Description: This test is based onto capture and high throw put sequencing adapted to cell free plasmatic DNA of pregnant women in order to detect point mutation present in her fetus. This approach has been previously described for others clinical applications such as liquid biopsy in cancers but not for NIPT analysis.
Study NCT04214938 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal solutions application were done including one solution for per patient before nasoendoscopy procedure according to randomization
Description: Hypertonic sea water, Vemcaine, Otrivine, and a placebo were applied by intranasal before the nasoendoscopy procedure for improving the field of view of clinician and reducing the patient discomfort.
Study NCT04214938 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal solutions application were done including one solution for per patient before nasoendoscopy procedure according to randomization
Description: Hypertonic sea water, Vemcaine, Otrivine, and a placebo were applied by intranasal before the nasoendoscopy procedure for improving the field of view of clinician and reducing the patient discomfort.
Study NCT04440527 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Preserflo / Innfocus Microshunt
Description: The Microshunt features an 8.5-mm tube with an outer diameter of 350 µm and a 70-µm diameter lumen. Implantation creates a subconjunctival bleb and lowers intraocular pressure by increasing aqueous humor outflow.
Study NCT04440527 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Trabeculectomy
Description: Trabeculectomy is the most commonly performed surgical procedure and is considered the gold standard.
Study NCT02559999 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Painful tonic stimuli
Study NCT02559999 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: non-painful stimuli
Study NCT01340846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Warfarin dosed at 15mg on Day 1 and Day 22
Study NCT01340846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Ketoconazole dosed at 400mg daily on Days 19 through 22
Study NCT01340846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Description: Gemfibrozil dosed at 600mg twice daily on Days 19 through 22
Study NCT01340846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2118436 150mg
Description: GSK2118436 dosed at 150mg twice daily
Study NCT01340846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2118436 75mg
Description: GSK2118436 dosed at 75mg twice daily
Study NCT04375085 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Percutaneous Coronary Intervention
Description: Percutaneous Coronary Intervention
Study NCT00740311 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MBCP gel TM
Description: alveoli filling with an injectable calcium phosphate after extraction of mandibular molar or pre molar
Study NCT00812019 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_0%MF59
Description: Two vaccinations of Cell Culture-Derived H5N1 3.75 µg Subunit Influenza Vaccine containing 0% of MF59.
Study NCT00812019 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_25%MF59
Description: Two vaccinations of Cell Culture-Derived H5N1 3.75 µg Subunit Influenza Vaccine containing 25% of MF59.
Study NCT00812019 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_50%MF59
Description: Two vaccinations of Cell Culture-Derived H5N1 3.75 µg Subunit Influenza Vaccine containing 50% of MF59.
Study NCT00812019 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_100%MF59
Description: Two vaccinations of Cell Culture-Derived H5N1 3.75 µg Subunit Influenza Vaccine containing 100% of MF59.
Study NCT00812019 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_0%MF59
Description: Two vaccinations of Cell Culture-Derived H5N1 7.5 µg Subunit Influenza Vaccine containing 0% of MF59.
Study NCT00812019 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_25%MF59
Description: Two vaccinations of Cell Culture-Derived H5N1 7.5 µg Subunit Influenza Vaccine containing 25% of MF59.
Study NCT00812019 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_50%MF59
Description: Two vaccinations of Cell Culture-Derived H5N1 7.5 µg Subunit Influenza Vaccine containing 50% of MF59.
Study NCT00812019 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_100%MF59
Description: Two vaccinations of Cell Culture-Derived H5N1 7.5 µg Subunit Influenza Vaccine containing 100% of MF59.
Study NCT00812019 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_0%MF59
Description: Two vaccinations of Cell Culture-Derived H5N1 15 µg Subunit Influenza Vaccine containing 0% of MF59.
Study NCT00812019 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_25%MF59
Description: Two vaccinations of Cell Culture-Derived H5N1 15 µg Subunit Influenza Vaccine containing 25% of MF59.
Study NCT00812019 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_50%MF59
Description: Two vaccinations of Cell Culture-Derived H5N1 15 µg Subunit Influenza Vaccine containing 50% of MF59.
Study NCT00812019 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_100%MF59
Description: Two vaccinations of Cell Culture-Derived H5N1 15 µg Subunit Influenza Vaccine containing 100% of MF59.
Study NCT01699438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalazine
Description: 2400 mg q.d. for 8 weeks
Study NCT01699438 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 tablets q.d. for 8 weeks
Study NCT01302990 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose given at Day 0
Description: Dose given by intramuscular administration (0.5 mL)
Study NCT01302990 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dose given at Day 0
Description: Dose given by intramuscular administration (0.5 mL)
Study NCT01302990 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Dose given at Day 0
Description: Dose given by intramuscular administration (0.5 mL)
Study NCT04349332 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Helmet non-invasive ventilation (NIV)
Description: After application of the helmet, arterial blood gas sampling will be utilized to follow gas-exchange; Noninvasive support will be reduced progressively in accordance to clinical improvement and will be discontinued if patient maintains respiratory rate \<30breaths/min and PaO2 >75mm Hg with FiO2 0.5 without ventilatory support. If endotracheal intubation is required, the helmet will be removed and the patient will be intubated without delay.
Study NCT04147780 — intervention group
Intervention type: PROCEDURE
Intervention: Sentinel node biopsy
Description: Sentinel node biopsy, radiotracer (mandatory) and blye dye (optional). Scintigraphy.
Study NCT02132429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 333
Description: Oral administration available in varying dose strength.
Study NCT02132429 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo containing no active drug
Study NCT00438009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coxsackievirus A21
Description: Two doses of drug, separated by 48 hours
Study NCT00775190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ortho tricyclen
Description: brand name oral contraceptive
Study NCT00775190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trinessa
Description: generic oral contraceptive
Study NCT04667130 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preventive Complex Program for Newly Diagnosed People With Multiple Sclerosis
Description: Preventive program included informations of the possibilities of physiotherapy in the treatment of multiple sclerosis focused on fatigue management - recommending lifestyle changes. Program included a the treatment of psychosomatic, viscerosomatic functional disorders by reflexively poor connection through the locomotor system using computer kinesiology, psychotherapy, manual therapy - where patients are corrected into a postural position and the joints are functionally centred, and aerobic exercise to influence fatigue and improve the performance of the cardiovascular system.
Study NCT03692299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saccharomyces Boulardii Oral Tablet
Description: Saccharomyces boulardii 200 mg b.i.d. during 2 weeks, followed by a 2-week rest period and then again 200 mg b.i.d. during 2 consecutive months.
Study NCT03692299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Metronidazole 500 mg b.i.d during 1 week, followed by a 3-week rest period and then again 500 mg b.i.d during 2 consecutive months
Study NCT00693901 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-based participatory research (CBPR)
Description: CBPR will involve park advisory boards and community members in the research process, including the park assessments and data analysis. The assessment research will be used to inform use of discretionary funds for park programming and facilities in the hopes of increasing community physical activity. Park directors will be provided with analysis of descriptive information and community feedback to help improve outreach, park programming, and features to attract more park users and increase physical activity.
Study NCT00693901 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Director-only
Description: Park directors will be provided with descriptive information on park use and community feedback. They will also receive assistance on how to improve outreach, programming, and park features that will increase park use and physical activity. These parks will not take part in any assessments.
Study NCT01376804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valganciclovir [Valcyte]
Description: Oral, daily for up to 200 days.
Study NCT00420771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: For the first week, one 400 mg Gabapentin capsule taken 3 times per day. For the second week, two 400 mg Gabapentin capsules taken 3 times per day. For the third week through the eighth week, three 400 mg Gabapentin capsules taken 3 times per day. For the ninth and last week, two 400 mg Gabapentin capsules taken 3 times per day for 3 days, then one 400 mg Gabapentin capsule taken 3 times per day for 4 days. Placebo study medication appears identical to active medication and is prescribed with an identical dosing schedule.
Study NCT00420771 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo comparator appears identical to active medication and is prescribed with an identical dosing schedule with a maximum dose of 400mg taken three times per day
Study NCT04004195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2327949
Description: A single oral dose of 30 mg BAY2327949 given as one 30 mg IR tablet (dose might be reduced to 15 mg for group 4 according to safety assessment team decision)
Study NCT01949818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yangzhengxiaoji capsule combined with CHOP regimen
Description: Yangzhengxiaoji capsule combined with CHOP regimen(Yangzhengxiaoji capsule,Cyclophosphamide,Vincristine,Doxorubicin,Prednisone)Yangzhengxiaoji capsule ,1.56g,Tid,p.o,d7-21, Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5.
Study NCT01949818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP regimen
Description: CHOP regimen(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5
Study NCT04427267 — intervention group
Intervention type: OTHER
Intervention: Personal protective equipment from biological hazard
Description: Includes: isolation clothing, mask, eyewear, overshoes
Study NCT00560196 — intervention group
Intervention type: OTHER
Intervention: Observation
Study NCT00641667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl 1-day application transdermal patch releasing the drug at the rate of 12.5 microgram per hour (mcg/hr) to 100 mcg/hr applied once daily, and maintained for 2 days. Dose escalation or reduction is as per Investigator's discretion (maximum applied dose is 300 mcg/hr) up to Day 7 and then dose is fixed for next 3 days that is Day 10 (end of treatment period).
Study NCT04271397 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Multiple blood samples
Description: Patients with active tuberculosis will have 5 research-specific blood samples: V1, (baseline) immediately before initiating anti-tuberculosis treatment, then 4 samples during anti-tuberculosis treatment and follow-up, i.e. at 48 hours (V2), 15 days (V3), 2 months (V4) and 6 months (V5) after initiation of treatment. The total volume of each sample will be 20 mL for a total of 100 mL.
Study NCT04271397 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Single blood sample
Description: Patients with Latent tuberculosis infection will have a single specific sample of 14 mL.
Study NCT03782506 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Music Therapy
Description: Ten 45-minutes individual interactive music therapy (IMT) sessions delivered by a board-certified music therapist. Sessions start with music-guided breathing or humming. The music therapist then engages the participant in singing of familiar songs and co-created vocal or instrumental music improvisations. Discussion about the meaning assigned to songs and emotions expressed through the improvisations follow. Each session involves learning and practicing music-based techniques for the self-management of pain, anxiety, stress, mood, fatigue, and sleep disturbance as these are common opioid withdrawal symptoms. Psychoeducation about opioid tapering is provided and tapering challenges experienced by the patient will be actively addressed through music-based interventions.
Study NCT03782506 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Verbal-based support
Description: Ten 45-minute individual sessions delivered by a master's level clinician with training in counseling. The sessions are focused on patient-initiated conversations about their pain, life stressors and the impact on their daily life. The intervener provides nondirective, supportive care by offering supportive, validating statements and reflective listening. The intervener refrains from employing active suggestion, problem-solving or behavioral or cognitive therapy techniques. The verbal support sessions are aimed at providing an empathic, therapeutic environment to facilitate emotional expression and sharing of worries and fears. As in the IMT protocol, psychoeducation about opioid tapering will be included and will be considered the only active treatment factor for this intervention.
Study NCT03713346 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lactose free milk
Description: Single dose of lactose free milk
Study NCT03713346 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Jersey milk
Description: Single dose of jersey milk
Study NCT03713346 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: High A1 β-casein milk
Description: Single dose of high A1 β-casein milk (commercial milk)
Study NCT03713346 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: High A2 β-casein milk
Description: Single dose of A2 β-casein milk
Study NCT01181349 — intervention group
Intervention type: OTHER
Intervention: Neuromuscular Blocking Agent (NMBA)
Description: While neuromuscular blockade drug(s) are involved in this study prior to actual study initiation (this is an observational study), it should be noted that the identity, combination(s), and dosages of these drugs (also referred to as general anesthesia drug\[s\]) are not specified in the protocol.
Study NCT00712439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin Extended Release tablets
Study NCT00712439 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02131506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib, Caelyx
Description: Lapatinib, Caelix: Lapatinib is given at escalating doses orally and continuously on days 1-21. Caelyx is administered at escalating doses in a 60-minute i.v. infusion on day 1. Each cycle is defined as 21 days. Four dose levels are planned. Dose level -1, Caelyx 30 mg/mq \& Lapatinib 1000 mg die; dose level 1, Caelyx 30 mg/mq \& Lapatinib 1250 mg die; dose level 2, Caelyx 30 mg/mq \& Lapatinib 1500 mg die; dose level 3, Caelyx 40 mg/mq \& Lapatinib 1500 mg die
Study NCT02338271 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: autologous adipose derived mesenchymal stem cell
Description: autologous adipose derived mesenchymal stem cell (2 x 10\^7 cells/mL /vial or 4 x 10\^7 cells/mL /vial) and Tissuefill (hyaluronic acid derivatives) 1mL/syringe
Study NCT03549767 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Springfusor
Description: Springfusor for administration of magnesium sulphate
Study NCT03549767 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Pritchard regimen. Magnesium sulphate is administered using hospital practice
Study NCT03298035 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NCPAP as mode for apnea prevention
Description: With recurrence of apneic events, infants on NCPAP will have changes made in NCPAP settings per the clinical team's discretion in attempt to prevent future apneic events. If apneic events persist despite NCPAP adjustments, clinicians may intubate based on clinical judgment.
Study NCT03298035 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIPPV as rescue mode for apnea prevention
Description: With recurrence of apneic events, infants will be placed on NIPPV with settings and adjustments per the clinical team's discretion. If apneic events persist despite NIPPV placement and setting adjustments, clinicians may intubate based on clinical judgment.
Study NCT02038933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT01759446 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo taken first
Description: Snorted in both nostrils within 5 minutes; 48 hours washout between doses
Study NCT01759446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Generic H/A taken first
Description: Snorted in both nostrils within 5 minutes; 48 hours washout between doses